The company has raised from several Silicon Valley firms making pioneering investments in generative AI and healthcare, including Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator.

Manual chart review can take hours per patient, and many health systems face significant backlogs in completing key oncology-related workflows for thousands of patients. This workload leads to clinical delays, such as patients missing out on clinical trials or biomarker-driven treatments, lagging quality reporting, and provider dissatisfaction and turnover.

Triomics Co-Founders Sarim Khan (CEO) and Hrituraj Singh (CTO) were college friends who later worked as an MIT biotech researcher and Adobe AI researchers, respectively. They knew software existed to quickly analyse the ~20% of medical data that is stored in a uniform, structured manner, like a patient’s demographics or laboratory values. However, they realised recent advances in generative AI created the possibility of similarly analysing the ~80% of medical data that exists in an unstructured format, like a doctor’s free-text note.

“Hrituraj and I decided to partner to build solutions leveraging the advances in the field of generative AI and LLMs to help hospital staff,” said Sarim Khan, CEO of Triomicss. “We want our solutions to reason and sound like experts in oncology.”

After developing an OncoLLM with Medical College of Wisconsin researchers, Triomics found that, in just minutes, it found 90% of eligible patients for clinical trials, which would have taken days or weeks for qualified nurses. It also extracted structured data points from unstructured notes at similar or higher accuracy to proprietary models like GPT4 or Claude while being 40 times cheaper. Triomics recently also published the results of its information retrieval engine for oncology, which they found to be 1.5-2x better than other state-of-the-art retrieval models.

“Most of the solutions on the market today claim to use GenAI. Triomics is different; they’ve taken a truly collaborative approach to co-developing these models,” said Bradley Taylor, Chief Research Informatics Officer at the Medical College of Wisconsin and Director of the CTSI Centre for Biomedical Informatics.

Anai Kothari, a surgical oncologist at the Medical College of Wisconsin Cancer Centre added: “The ability to quickly and accurately convert complex cancer data into a format that can be used to improve patient care is crucial. Triomics has integrated our suggestions and then rigorously studied their approach to ensure it provides relevant results.”

OncoLLM powers proprietary Triomics software that integrates with health system EHRs to complete specific clinical and administrative tasks. For example, Triomics Prism aids in patient-trial matching by pre-screening oncology patients with upcoming appointments to find relevant clinical trials. Triomics Harmony curates EHR data to support quality reporting, cohort analysis and precision oncology.

Hrituraj Singh, CTO at Triomics, commented: “Our investments in our core areas of focus have been deliberate. We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialised in customising language models to specific domains, and our clinical staff, who have decades of oncology-specific experience. As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.”

Given the heightened importance of accuracy for oncology data, Triomics partners with leading academic cancer centres and researchers to develop generative AI performance and safety benchmarks and best practices. Partners include the Collaboration for Oncology-focused LLM Training (COLT), a consortium of leaders from a dozen NCI-designated cancer centres, and the Cancer Informatics for Cancer Centres (CI4CC) Society.

“We differentiate ourselves by building tailored models specifically for oncology and pairing them with GenAI native workflows,” said Sarim Khan. “While other solutions address some of the use cases we’re working on, like patient-trial matching, they are broad-based solutions that use or modify legacy technologies that have proven not to have the scalability or ROI the industry is requesting.”

Triomics next plans to publish additional data on OncoLLM efficacy across a diversity of settings and patient populations, and develop software that powers additional use cases.

“Triomics is leveraging existing healthcare datasets and Generative AI to empower hospital staff to automate clinical trials and streamline cancer centre workflows,” said Dev Khare, partner at Lightspeed. “We are excited to back Triomics in this important mission.”

“With robust early results for their proprietary oncology specific LLMs and partnerships with leading cancer care and research centres, Triomics is well poised to deliver significant value to cancer care providers and patients in the U.S. and globally,” said Jishnu Bhattacharjee, managing director at Nexus Venture Partners. “We are thrilled to partner with Sarim and Hrituraj to help build a remarkably impactful company!"